Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Gastrointestinal tumours, non-colorectal

3222 - Nab-paclitaxel (Nab) plus Gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): the GAP trial, a GISCAD phase II comparative randomized trial.

Date

28 Sep 2019

Session

Poster Discussion – Gastrointestinal tumours, non-colorectal

Presenters

Stefano Cascinu

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

S. Cascinu1, R. Berardi2, R. Bianco3, D. Bilancia4, A. Zaniboni5, D. Ferrari6, S. Mosconi7, A. Spallanzani8, L. Cavanna9, S. Leo10, F. Negri11, G.D. Beretta12, A. Sobrero13, M. banzi14, A. Morabito15, A. Bittoni2, R. Marciano3, D. Ferrara4, S. Noventa5, M.C. Piccirillo16

Author affiliations

  • 1 Oncology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 2 Clinical Oncology, Dept. Of Internal Medicine, AOU Ospedali Riuniti Ancona, 60126 - Torrette di Ancona/IT
  • 3 Dipartimento Di Medicina Clinica E Chirurgica, Università Federico II, 80131 - Napoli/IT
  • 4 Oncologia, AZ. OSPEDALIERA SAN CARLO, 85100 - Potenza/IT
  • 5 Medical Oncology, Casa di Cura Poliambulanza, 25124 - Brescia/IT
  • 6 Oncologia Medica, A. O. San Paolo, 20142 - Milano/IT
  • 7 Oncologia Medica, A.O. Papa Giovanni XXIII, 24127 - Bergamo/IT
  • 8 Oncologia Medica, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41100 - Modena/IT
  • 9 Oncologia Medica E Ematologia, USL di Piacenza - Ospedale Guglielmo da Saliceto, 29100 - Piacenza/IT
  • 10 Oncologia Medica, A.O. Vito Fazi, 73100 - Lecce/IT
  • 11 Oncologia, Azienda Ospedaliera Universitaria di Parma, 43126 - Parma/IT
  • 12 Oncologia, Humanitas Gavazzeni, 24125 - Bergamo/IT
  • 13 Department Of Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 16132 - Genova/IT
  • 14 Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 15 Oncologia, ULSS6 EUGANEA P.O. Cittadella-Camposampiero, 35012 - Camposampiero/IT
  • 16 Clinical Trials Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione G. Pascale, 80131 - Napoli/IT

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3222

Background

The role of a combination therapy is defined in metastatic pancreatic cancer but not in LAUPC. Lacking dedicated randomized trials, evidence mostly comes from retrospective or phase II studies. G alone remains the standard option following a subgroup LAUPC analysis of a GERCOR/GISCAD trial (J Clin Oncol 2005).

Methods

GAP is a multicentre, open-label, randomized, comparative phase II trial testing the efficacy of NabG vs G. Patients ≤75 years, PS 0-1, were randomized 1:1 to Nab/G (Nab 125 mg/mq plus G 1000 mg/mq on days 1, 8 and 15 every 28 days for 3 cycles) or G (same schedule and doses). Patients not progressing after 3 cycles had to receive capecitabine plus radiotherapy for 5 weeks. Disease progression rate (DPR) according to RECIST 1.1 after 3 cycles of chemotherapy is the primary endpoint. With 80% power in detecting a reduction of DPR from 40% to 20%, one-tailed alpha=0.05, 124 patients were required. Progression-free survival (PFS) is a secondary endpoint; with 109 events the study has 80% power, with one-tailed alpha=0.05, to detect a 0.62 hazard ratio of PFS.

Results

124 patients were enrolled in this trial (4 withdrew consent after randomization in the G arm). Most of the patients were PS 0 (65.8%), and women (56.7%). The study met its primary endpoint DPR, with a reduction from 45.6% with G to 25.4% with Nab/G. There was no unexpected toxicity. One patient died during treatment with G due to a stroke.Table:

673PD

ArmPatientsDPROne-tail chi squareMedian PFS (102 events)HR of PFSProgression at distant siteMedian OS (82 events)HR of OS
G5726 (45.6%)P = 0.015.1 mos0.71 (90% CI 0.51-0.99)18/2610.7 mos0.65 (90% CI 0.44-0.94)
NabG6316 (25.4%)7.6 mos6/1613.1 mos

Conclusions

NabG reduces the rate of LAUPC patients who progress after 3 cycles of chemotherapy compared with G, especially in terms of distant relapses, positively affecting PFS and overall survival. Nowadays it should be the therapeutic option in this setting.

Clinical trial identification

NCT02043730; 2013-002973-23.

Editorial acknowledgement

Legal entity responsible for the study

Fondazione GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente).

Funding

Celgene.

Disclosure

S. Cascinu: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Servier; Advisory / Consultancy: Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Celgene; Honoraria (self): Sanofi; Research grant / Funding (self): Eisai. R. Bianco: Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Italfarmaco; Advisory / Consultancy: AstraZeneca. D. Ferrari: Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Bristol-Meyers Squibb; Travel / Accommodation / Expenses: Roche. L. Cavanna: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Pfizer; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Celgene. G.D. Beretta: Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Servier; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Taiho Pharmaceutical. A. Sobrero: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: Servier; Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Advisory / Consultancy, Speaker Bureau / Expert testimony: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Takeda; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Bristol-Meyers Squibb. A. Morabito: Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Ipsen; Honoraria (self): Delphi Diagnostics; Honoraria (self): Servier; Research grant / Funding (institution): Celgene. M.C. Piccirillo: Advisory / Consultancy: Glaxo; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Travel / Accommodation / Expenses: Bayer; Honoraria (self): MSD; Research grant / Funding (institution): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.